Jinadasa A G R Greshamali, Akalanka H M Kasuni, Wageesha N D Amal, Ekanayake Sagarika
Department of Basic Sciences Faculty of Allied Health Sciences University of Sri Jayewardenepura, Gangodawila, Nugegoda, Sri Lanka.
Rural Health Research Institute Charles Sturt University Orange, Orange, NSW 2800, Australia.
Int J Breast Cancer. 2024 Aug 27;2024:1094274. doi: 10.1155/2024/1094274. eCollection 2024.
Metformin (MET) is the commonly prescribed hypoglycemic agent used in the treatment of type 2 diabetes mellitus (DM). Pleiotropic effects of MET are emerging as a medication for other diseases including breast cancer (BC). Therefore, a literature review was conducted to investigate whether the anticancer effects of MET are mediated through adenosine monophosphate kinase (AMPK). This review assessed published data focusing on studies where BC cell lines were treated with MET to explore its potential anticancer effects via AMPK on BC cells. The published data reveals that activated AMPK induces anticancer effects primarily by suppressing cell proliferation, induction of apoptosis, and cell cycle arrest, inhibition of metastasis and invasion, alteration of tumor microenvironment, and downregulation of tumorigenesis. In addition, MET was observed to induce AMPK-mediated effects when combined with other drugs. Further studies on assessing the potential use of MET alone or in combination with other drugs would pave the way to design new treatment strategies for BC.
二甲双胍（MET）是治疗2型糖尿病（DM）时常用的降糖药物。二甲双胍的多效性正使其成为包括乳腺癌（BC）在内的其他疾病的治疗药物。因此，我们进行了一项文献综述，以研究二甲双胍的抗癌作用是否通过单磷酸腺苷激酶（AMPK）介导。本综述评估了已发表的数据，重点关注用二甲双胍处理乳腺癌细胞系的研究，以探讨其通过AMPK对乳腺癌细胞的潜在抗癌作用。已发表的数据表明，激活的AMPK主要通过抑制细胞增殖、诱导凋亡和细胞周期停滞、抑制转移和侵袭、改变肿瘤微环境以及下调肿瘤发生来发挥抗癌作用。此外，当二甲双胍与其他药物联合使用时，可观察到其诱导AMPK介导的效应。进一步评估二甲双胍单独或与其他药物联合使用的潜在用途的研究，将为设计新的乳腺癌治疗策略铺平道路。
